461 related articles for article (PubMed ID: 25318801)
1. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
Takeda T; Itano H; Fukita S; Saitoh M; Takeda S
Intern Med; 2014; 53(20):2347-51. PubMed ID: 25318801
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
Tsao AS; Harun N; Lee JJ; Heymach J; Pisters K; Hong WK; Fujimoto J; Wistuba I
Clin Lung Cancer; 2014 May; 15(3):197-201. PubMed ID: 24492162
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
Toyokawa G; Takenoyama M; Hirai F; Toyozawa R; Inamasu E; Kojo M; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Shimokawa M; Seto T; Ichinose Y
Int J Clin Oncol; 2014 Aug; 19(4):601-6. PubMed ID: 24158772
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
Hassan R; Kindler HL; Jahan T; Bazhenova L; Reck M; Thomas A; Pastan I; Parno J; O'Shannessy DJ; Fatato P; Maltzman JD; Wallin BA
Clin Cancer Res; 2014 Dec; 20(23):5927-36. PubMed ID: 25231400
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.
Jing XQ; Zhou L; Sun XD; Yu JM; Meng X
Medicine (Baltimore); 2016 Apr; 95(14):e3351. PubMed ID: 27057918
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
[TBL] [Abstract][Full Text] [Related]
7. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
Shukuya T; Takahashi T; Imai H; Tokito T; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Yamamoto N
Respir Investig; 2014 Mar; 52(2):101-6. PubMed ID: 24636265
[TBL] [Abstract][Full Text] [Related]
8. Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.
Cihan YB; Ozturk A; Mutlu H
Asian Pac J Cancer Prev; 2014; 15(5):2061-7. PubMed ID: 24716935
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.
van den Bogaert DP; Pouw EM; van Wijhe G; Vernhout RM; Surmont VF; Hoogsteden HC; van Klaveren RJ
J Thorac Oncol; 2006 Jan; 1(1):25-30. PubMed ID: 17409823
[TBL] [Abstract][Full Text] [Related]
11. Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed.
Hayashi H; Okamoto I; Ichikawa Y; Miyazaki M; Yoshioka H; Kunimasa K; Nakagawa K
Int J Clin Oncol; 2010 Oct; 15(5):497-9. PubMed ID: 20224880
[TBL] [Abstract][Full Text] [Related]
12. Standard therapy for the treatment of malignant pleural mesothelioma.
Vogelzang NJ
Lung Cancer; 2005 Oct; 50 Suppl 1():S23-4. PubMed ID: 16291429
[TBL] [Abstract][Full Text] [Related]
13. Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.
Maehara S; Usuda J; Ishizumi T; Ichinose S; Ohtani K; Inoue T; Imai K; Furumoto H; Kudo Y; Kajiwara N; Ohira T; Ikeda N
Int J Oncol; 2015 Feb; 46(2):741-9. PubMed ID: 25385189
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
18. Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements.
Christoph DC; Eberhardt WE
Curr Opin Oncol; 2014 Mar; 26(2):171-81. PubMed ID: 24441503
[TBL] [Abstract][Full Text] [Related]
19. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
[TBL] [Abstract][Full Text] [Related]
20. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]